Molecular biology of prostate cancer

被引:44
作者
Schulz, WA [1 ]
Burchardt, M [1 ]
Cronauer, MV [1 ]
机构
[1] Univ Dusseldorf, Dept Urol, D-40225 Dusseldorf, Germany
关键词
androgens; epigenetics; expression profiling; oncogene; tumour suppressor;
D O I
10.1093/molehr/gag064
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
In spite of progress in diagnosis and treatment, prostate cancer has become one of the most frequent lethal cancers in males in many Western industrialized countries. Research on the molecular biology of prostate cancer is expected to reveal those aspects of Western lifestyle contributing to its high incidence with the aims of improving prevention, distinguishing slow-growing from aggressive clinically relevant cancers, and providing targets for treatment, particularly of locally advanced and of metastatic disease. Traditionally, prostate cancer research focused on androgens. More recently, tumour suppressors and proto-oncogenes important in other human cancers have been intensely investigated. Current approaches include the search for genes mutated in familial cases, identification of recurrent chromosomal alterations and their associated potential tumour suppressor genes, determination of gene expression profiles characterizing tumour stages and subclasses, and elucidation of the importance of epigenetic alterations. Results from such studies have begun to be translated into the clinic. Further successful transfer of results from molecular biology to the clinic will, however, require integration of the amassed molecular data into a biological framework model of prostate carcinoma.
引用
收藏
页码:437 / 448
页数:12
相关论文
共 158 条
[1]   Molecular genetics of prostate cancer [J].
Abate-Shen, C ;
Shen, MM .
GENES & DEVELOPMENT, 2000, 14 (19) :2410-2434
[2]   Tumour class prediction and discovery by microarray-based DNA methylation analysis -: art. no. e21 [J].
Adorján, P ;
Distler, J ;
Lipscher, E ;
Model, F ;
Müller, J ;
Pelet, C ;
Braun, A ;
Florl, AR ;
Gütig, D ;
Grabs, G ;
Howe, A ;
Kursar, M ;
Lesche, R ;
Leu, E ;
Lewin, A ;
Maier, S ;
Müller, V ;
Otto, T ;
Scholz, C ;
Schulz, WA ;
Seifert, HH ;
Schwope, I ;
Ziebarth, H ;
Berlin, K ;
Piepenbrock, C ;
Olek, A .
NUCLEIC ACIDS RESEARCH, 2002, 30 (05) :e21
[3]   Identification of genetic markers for prostatic cancer progression [J].
Alers, JC ;
Rochat, J ;
Krijtenburg, PJ ;
Hop, WCJ ;
Kranse, R ;
Rosenberg, C ;
Tanke, HJ ;
Schröder, FH ;
van Dekken, H .
LABORATORY INVESTIGATION, 2000, 80 (06) :931-942
[4]   Biology of prostate-specific antigen [J].
Balk, SP ;
Ko, YJ ;
Bubley, GJ .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (02) :383-391
[5]  
Banham AH, 2001, CANCER RES, V61, P8820
[6]  
BEDFORD MT, 1987, CANCER RES, V47, P5274
[7]  
Bednarek AK, 2000, CANCER RES, V60, P2140
[8]  
BERCHEM GJ, 1995, CANCER RES, V55, P735
[9]   Hereditary prostate cancer: Clinical aspects [J].
Bratt, O .
JOURNAL OF UROLOGY, 2002, 168 (03) :906-913
[10]   Hormone therapy failure in human prostate cancer:: Analysis by complementary DNA and issue microarrays [J].
Bubendorf, L ;
Kolmer, M ;
Kononen, J ;
Koivisto, P ;
Mousses, S ;
Chen, YD ;
Mahlamäki, E ;
Schraml, P ;
Moch, H ;
Willi, N ;
Elkahloun, AG ;
Pretlow, TG ;
Gasser, TC ;
Mihatsch, MJ ;
Sauter, G ;
Kallioniemi, OP .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (20) :1758-1764